HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial - PubMed
3 days ago
- #clinical trial
- #antibody-drug conjugate
- #lung cancer
- HS-20093 is a B7-H3-targeted antibody-drug conjugate evaluated in the ARTEMIS-001 phase 1a/b trial for advanced solid tumors, including lung cancer.
- The maximum tolerated dose was established at 12.0 mg/kg in phase 1a.
- Common grade ≥3 treatment-related adverse events included decreased neutrophil counts (25.5%-50.5%), white blood cell counts (19.7%-42.4%), and anemia (16.8%-34.3%).
- Treatment-related interstitial lung disease occurred in 3.4% of patients, and AEs leading to death occurred in 3.8%.
- Confirmed objective response rates were 52.3% for ES-SCLC and 22.4% for NSCLC patients.
- The 8.0 mg/kg dose was selected for phase 3 trials based on comparable efficacy between 8.0 mg/kg and 10.0 mg/kg cohorts.